Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fat.

Literature DB >> 34643917

Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fat.

Abstract

Epicardial adipose tissue is a novel cardiovascular risk factor. It plays a role in the progression of coronary artery disease, heart failure and atrial fibrillation. Given its rapid metabolism, clinical measurability, and modifiability, epicardial fat works well as therapeutic target of drugs modulating the adipose tissue. Epicardial fat responds to glucagon-like peptide 1 receptor agonists (GLP1A) and sodium glucose co-transporter 2 inhibitors (SGLT2i). GLP-1A and SGLT2i provide weight loss and cardiovascular protective effects beyond diabetes control, as recently demonstrated. The potential of modulating the epicardial fat morphology and genetic profile with targeted pharmacological agents can open new avenues in the pharmacotherapy of diabetes and obesity, with particular focus on cardiovascular risk reduction.

Entities: Chemical

Keywords: Diabetes; Epicardial adipose tissue; Epicardial fat; Glucagon like peptide 1 receptor agonists; Heart failure; Obesity; Sodium glucose co-transporter 2 inhibitors

Mesh：

Substances：

Year: 2021 PMID： 34643917 DOI： 10.1007/s40618-021-01687-1

Source DB: PubMed Journal: J Endocrinol Invest ISSN： 0391-4097 Impact factor: 4.256

58 in total

Review 1. Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart.

Authors: Gianluca Iacobellis; Domenico Corradi; Arya M Sharma
Journal: Nat Clin Pract Cardiovasc Med Date: 2005-10

2. Secretory type II phospholipase A2 is produced and secreted by epicardial adipose tissue and overexpressed in patients with coronary artery disease.

Authors: Anne Dutour; Vincent Achard; Henrike Sell; Nadia Naour; Frederic Collart; Benedicte Gaborit; Alina Silaghi; Juergen Eckel; Marie-Christine Alessi; Corneliu Henegar; Karine Clément
Journal: J Clin Endocrinol Metab Date: 2009-12-11 Impact factor: 5.958

3. Uncoupling protein-1 and related messenger ribonucleic acids in human epicardial and other adipose tissues: epicardial fat functioning as brown fat.

Authors: Harold S Sacks; John N Fain; Ben Holman; Paramjeet Cheema; Aron Chary; Frank Parks; James Karas; Robert Optican; Suleiman W Bahouth; Edward Garrett; Rodney Y Wolf; Russell A Carter; Todd Robbins; David Wolford; Joseph Samaha
Journal: J Clin Endocrinol Metab Date: 2009-06-30 Impact factor: 5.958

Review 4. Local and systemic effects of the multifaceted epicardial adipose tissue depot.

Authors: Gianluca Iacobellis
Journal: Nat Rev Endocrinol Date: 2015-04-07 Impact factor: 43.330

5. Coronary atherosclerosis is associated with macrophage polarization in epicardial adipose tissue.

Authors: Yoichiro Hirata; Minoru Tabata; Hirotsugu Kurobe; Tatsuo Motoki; Masashi Akaike; Chika Nishio; Mayuko Higashida; Hiroaki Mikasa; Yutaka Nakaya; Shuichiro Takanashi; Takashi Igarashi; Tetsuya Kitagawa; Masataka Sata
Journal: J Am Coll Cardiol Date: 2011-07-12 Impact factor: 24.094

6. Epicardial adipokines in obesity and coronary artery disease induce atherogenic changes in monocytes and endothelial cells.

Authors: Kalypso Karastergiou; Ian Evans; Nicola Ogston; Nazar Miheisi; Devaki Nair; Juan-Carlos Kaski; Marjan Jahangiri; Vidya Mohamed-Ali
Journal: Arterioscler Thromb Vasc Biol Date: 2010-04-15 Impact factor: 8.311

Review 7. Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features.

Authors: Gianluca Iacobellis; Antonio C Bianco
Journal: Trends Endocrinol Metab Date: 2011-08-16 Impact factor: 12.015

8. Adult epicardial fat exhibits beige features.

Authors: Harold S Sacks; John N Fain; Suleiman W Bahouth; Shalini Ojha; Andrea Frontini; Helen Budge; Saverio Cinti; Michael E Symonds
Journal: J Clin Endocrinol Metab Date: 2013-07-03 Impact factor: 5.958

9. Human epicardial adipose tissue is a source of inflammatory mediators.

Authors: Tomasz Mazurek; LiFeng Zhang; Andrew Zalewski; John D Mannion; James T Diehl; Hwyda Arafat; Lea Sarov-Blat; Shawn O'Brien; Elizabeth A Keiper; Anthony G Johnson; Jack Martin; Barry J Goldstein; Yi Shi
Journal: Circulation Date: 2003-10-27 Impact factor: 29.690

Review 5. The Predictive Value of Epicardial Fat Tissue Volume in the Occurrence and Development of Atrial Fibrillation: A Systematic Review and Meta-Analysis.

Authors: Qiankun Fan; Yinge Zhan; Mingqi Zheng; Fangfang Ma; Lishuang Ji; Lei Zhang; Gang Liu
Journal: Cardiol Res Pract Date: 2022-09-29 Impact factor: 1.990

5 in total

Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fat.

Review 1. Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart.

2. Secretory type II phospholipase A2 is produced and secreted by epicardial adipose tissue and overexpressed in patients with coronary artery disease.

3. Uncoupling protein-1 and related messenger ribonucleic acids in human epicardial and other adipose tissues: epicardial fat functioning as brown fat.

Review 4. Local and systemic effects of the multifaceted epicardial adipose tissue depot.

5. Coronary atherosclerosis is associated with macrophage polarization in epicardial adipose tissue.

6. Epicardial adipokines in obesity and coronary artery disease induce atherogenic changes in monocytes and endothelial cells.

Review 7. Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features.

8. Adult epicardial fat exhibits beige features.

9. Human epicardial adipose tissue is a source of inflammatory mediators.

Review 10. Myocardial, perivascular, and epicardial fat.

1. Obesity and HFpEF.

2. Semaglutide in routine clinical practice: interesting news from real-world evidence.

Review 3. Non-canonical WNT signalling in cardiovascular disease: mechanisms and therapeutic implications.

4. Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients.

Review 5. The Predictive Value of Epicardial Fat Tissue Volume in the Occurrence and Development of Atrial Fibrillation: A Systematic Review and Meta-Analysis.